MyelinWatch EL
← Pipeline
Planned / announced human trialAnnounced / plannedRegulatory development

Phase 2 • planned

Lucid-MS / Lucid-21-302

PAD2 inhibitor • progressive MS

Compound / intervention
PAD2 inhibitor • progressive MS
Mechanism
PAD2 inhibition
Development stage
Phase 2 • planned
Status
FDA IND cleared • public trial registration not located
Population / locations
Sites have not been published • not recruiting in Greece
Evidence level
Human development milestone • no MS efficacy data
Next substantive checkpoint

Public Phase 2 registration, sites and recruitment opening

Company filingOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Planned / announced human trialAnnounced / plannedRegulatory development

Phase 2 • planned

Lucid-MS: FDA lifts the clinical hold, allowing a planned Phase 2 to move forward

After an earlier clinical hold, the FDA allowed the Lucid-MS IND to proceed. The company plans a randomised, double-blind, placebo-controlled Phase 2 in progressive MS for the PAD2 inhibitor Lucid-21-302.

What this means clinically

This is permission to begin clinical development, not evidence that the drug remyelinates or improves outcomes. As of 16 September 2026, no public Phase 2 registration or recruiting site had been located.

Source quality: Official company SEC filing • not a peer-reviewed efficacy result

Company filingSEC filing / Quantum BioPharma ↗